Last edition
News about "Marc Falkin"
Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Marc Falkin | 04/09/2026 | By News Bureau | 100
Cipla Wins US FDA Approval for Generic Advair Diskus
Cipla has received US Food and Drug Administration (FDA) approval for its generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all 3 strengths.
Marc Falkin | 29/07/2026 | By News Bureau | 128
Cipla Launches Saxenda for Weight Management
Cipla has strengthened its US portfolio with the launch of a generic version of Saxenda (liraglutide injection), indicated for chronic weight management. The launch follows ANDA approval from the US Food and Drug Administration (FDA), granted to its partner Orbicular, paving the way for expanded access to a more affordable GLP-1 therapy in the US.
Marc Falkin | 02/03/2026 | By News Bureau | 277
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy